Evidence map›Paper›PMID 20668552›Full record

ArticlePloS one2010

Bcl-2 regulates HIF-1alpha protein stabilization in hypoxic melanoma cells via the molecular chaperone HSP90.

Daniela Trisciuoglio, Chiara Gabellini, Marianna Desideri, Elio Ziparo, Gabriella Zupi, Donatella Del Bufalo

RetractedOpen access · goldAbstract readRetracted Publication
In one paragraph

Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 90 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Hypoxia-dependent drivers of melanoma progression.Journal of experimental & clinical cancer research : CR · 2021
    Review
  10. Article
  11. Review
  12. Inhibitors of HSP90 in melanoma.Apoptosis : an international journal on programmed cell death · 2020
    Review
  13. Review
  14. Semaphorin 5A drives melanoma progression: role of Bcl-2, miR-204 and c-Myb.Journal of experimental & clinical cancer research : CR · 2018
    Article
  15. Article
  16. BCL-XCell death & disease · 2017
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Daniela TrisciuoglioExperimental Chemotherapy Laboratory, Regina Elena Cancer Institute, Rome, Italy.
Chiara Gabellini
Marianna Desideri
Elio Ziparo
Gabriella Zupi
Donatella Del Bufalo
Cancer Institute (WIA) · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHypoxia-Inducible Factor 1 (HIF-1) is a transcription factor that is a critical mediator of the cellular response to hypoxia. Enhanced levels of HIF-1alpha, the oxygen-regulated subunit of HIF-1, is often associated with increased tumour angiogenesis, metastasis, therapeutic resistance and poor prognosis. It is in this context that we previously demonstrated that under hypoxia, bcl-2 protein promotes HIF-1/Vascular Endothelial Growth Factor (VEGF)-mediated tumour angiogenesis. METHODOLOGY/PRINCIPAL

findingsBy using human melanoma cell lines and their stable or transient derivative bcl-2 overexpressing cells, the current study identified HIF-1alpha protein stabilization as a key regulator for the induction of HIF-1 by bcl-2 under hypoxia. We also demonstrated that bcl-2-induced accumulation of HIF-1alpha protein during hypoxia was not due to an increased gene transcription or protein synthesis. In fact, it was related to a modulation of HIF-1alpha protein expression at a post-translational level, indeed its degradation rate was faster in the control lines than in bcl-2 transfectants. The bcl-2-induced HIF-1alpha stabilization in response to low oxygen tension conditions was achieved through the impairment of ubiquitin-dependent HIF-1alpha degradation involving the molecular chaperone HSP90, but it was not dependent on the prolyl hydroxylation of HIF-1alpha protein. We also showed that bcl-2, HIF-1alpha and HSP90 proteins form a tri-complex that may contribute to enhancing the stability of the HIF-1alpha protein in bcl-2 overexpressing clones under hypoxic conditions. Finally, by using genetic and pharmacological approaches we proved that HSP90 is involved in bcl-2-dependent stabilization of HIF-1alpha protein during hypoxia, and in particular the isoform HSP90beta is the main player in this phenomenon. CONCLUSIONS/SIGNIFICANCE: We identified the stabilization of HIF-1alpha protein as a mechanism through which bcl-2 induces the activation of HIF-1 in hypoxic tumour cells involving the beta isoform of molecular chaperone HSP90.

Indexed as

BenzoquinonesBlotting, WesternCell HypoxiaCell Line, TumorEnzyme-Linked Immunosorbent AssayHSP90 Heat-Shock ProteinsHumansHypoxia-Inducible Factor 1, alpha SubunitImmunoprecipitationLactams, MacrocyclicMelanomaMicroscopy, ConfocalProtein BindingProtein IsoformsProtein StabilityProto-Oncogene Proteins c-bcl-2BenzoquinonesHIF1A protein, humanHSP90 Heat-Shock ProteinsHypoxia-Inducible Factor 1, alpha SubunitLactams, MacrocyclicProtein IsoformsProto-Oncogene Proteins c-bcl-2tanespimycinUbiquitin

Identifiers

PMID20668552
PMCPMC2910721
OpenAlexW1999680285

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.